In Hepatitis, One Transformation May Soon Be Followed By Next
SAN FRANCISCO – Hepatitis C treatment is in a strange space right now. The approval earlier this year of the first two direct-acting antiviral drugs, Incivek (telaprevir, Vertex Pharmaceuticals Inc.) and Victrelis (boceprevir, Merck & Co. Inc.) has brought new options to hepatitis C patients.
The approval of telaprevir and boceprevir has already prompted the American Association for the Study of Liver Diseases to release new treatment guidelines for hepatitis C.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter